VEGFA and hepatocellular carcinoma: A randomized, open-label, multicenter trial (NCT03794440) in China has shown the acceptable safety of the combination of sintilimab (anti-PD1 mAb) and bevacizumab (anti-VEGF mAb) as a first-line treatment in patients with advanced HCC.